Novo beats Lilly to first FDA-approved GLP-1RA pill for obesity
Shares rose 5% for Novo Nordisk as it looks to ease market pressures with a significant revenue stream.
Therapy Area
UK approves Gilead’s twice-yearly HIV PrEP drug
Nxera seeks schizophrenia programme buyer after Boehringer snub
CDC ends universal newborn hepatitis B vaccine recommendations
Precision medicine approaches needed in oncology to match evolving SoC
First gonorrhoea antibiotics in decades herald new era of treatment
Sanofi shares fall 6% after double setback for MS drug tolebrutinib
Mirum to buy Bluejay for up to $820m in rare liver disease push
